NeoPharm, Inc. (NASDAQ:NEOL), Waukegan, Ill., has announced its fourth quarter and full year 2007 financial results.
For the fourth quarter ended December 31, 2007, NeoPharm reported a net loss of $1.1 million, or ($0.04) per basic and diluted share, as compared to a net loss of $7.7 million, or ($0.28) per share, for the same period last year. The net loss for the quarter includes a credit to research and development expenses of $0.9 million, or $0.03 per diluted share, related to an adjustment to reduce accrued clinical trial expenses for the PRECISE trial from the estimated costs provided as patients were enrolled in the trial to the actual final trial costs. Excluding ...